Immunological Biomarkers and Epidemiological Evaluation of Lymphatic Filariasis Elimination Efforts in Osun State, Nigeria

Notice

This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.

Year : 2026 | Volume : 3 | 01 | Page :
    By

    Nzekwe Samuel C,

  • Babarinde Samuel O.,

  • Morakinyo Adetoun E.,

  • Boladale Abiodun L.,

  • Adeyemo Tolulope A.,

  • Kehinde Damilale O.,

  • Adeyemo Temitayo A.,

  • Ogundinmu Marvelous O.,

  • Oyebamiji David A.,

  • Oladunni Opeyemi,

  • Okorie Anyaele O.,

  • Adejumobi Musibau O.,

  • Ayeleso Ademola O.,

  • Odaibo Alexander B.,

  1. Researcher, Faculty of Science, Adeleke University, Ede 232101, Osun State, Nigeria
  2. Researcher, Faculty of Science, Adeleke University, Ede 232101, Osun State, Nigeria
  3. Researcher, Faculty of Science, Adeleke University, Ede 232101, Osun State, Nigeria
  4. Researcher, Department of Public Health, Ministry of Health, Osun State, Nigeria.
  5. Researcher, Obafemi Awolowo University Teaching Hospital, Ile-Ife, Osun State, Nigeria.
  6. Researcher, Faculty of Science, Adeleke University, Ede 232101, Osun State, Nigeria
  7. Researcher, University of Osun Teaching Hospital, Osogbo, Osun State, Nigeria.
  8. Researcher, Faculty of Science, Adeleke University, Ede 232101, Osun State, Nigeria
  9. Researcher, Department of Zoology, University of Ibadan, Oyo State, Nigeria
  10. Researcher, Department of Public Health, Adeleke University, Ede 232101, Osun State, Nigeria
  11. Researcher, Department of Zoology, University of Ibadan, Oyo State, Nigeria
  12. Researcher, Department of Surgery, University of Osun Teaching Hospital, Osogbo, Osun State, Nigeria
  13. Researcher, Life Sciences, University of South Africa, South Africa, South Africa
  14. Researcher, Department of Zoology, University of Ibadan, Oyo State, Nigeria

Abstract

Lymphatic filariasis (LF) remains a neglected tropical disease affecting millions globally, despite extensive elimination efforts. While the interruption of transmission is a key goal, the long-term immunological effects on individuals with existing complications like elephantiasis remain poorly understood. This study assessed the current transmission status of LF and the haematological profiles of infected individuals across selected Local Government Areas (LGAs) in Osun State, Nigeria. A total of 7,388 individuals from 12 LGAs were screened for circulating filarial antigen (CFA) using Abbott Filarial Test Strips (FTS). Additionally, haematological parameters, including white blood cells (WBCs), lymphocytes, monocytes, neutrophils, and eosinophils, were evaluated in five previously diagnosed LF patients to determine immune cell modulation associated with chronic infection. The pre-transmission assessment survey (pre-TAS) yielded a 0% antigenemia rate across all 12 LGAs, which falls within the WHO threshold (< 2%) for the cessation of mass drug administration (MDA). This indicates probable interruption of LF transmission in Osun State. Data from the community survey also revealed moderate compliance with preventive measures, with 41.09% of participants reporting sleeping under long-lasting insecticide-treated nets (LLINs), and 56.09% reporting participation MDA. Haematological assessments revealed significant variations in immune cell profiles among the LF patients. While some exhibited a reduction in WBCs, lymphocytes, suggestive of immune suppression, others displayed elevated counts consistent with active immune response or recovery. Persistent monocytosis and eosinophil reduction were common, indicating ongoing immune modulation despite parasite clearance. It is concluded that Osun State has entered the post-transmission phase of LF elimination, reflecting the effectiveness of sustained MDA and vector control interventions. Nonetheless, continued immune monitoring, post-MDA surveillance, and improved LLIN usage are essential to prevent reinfection and ensure lasting elimination.

Keywords: Lymphatic filariasis; immune cells; circulating filarial antigen; mass drug administration, post-elimination surveillance

How to cite this article:
Nzekwe Samuel C, Babarinde Samuel O., Morakinyo Adetoun E., Boladale Abiodun L., Adeyemo Tolulope A., Kehinde Damilale O., Adeyemo Temitayo A., Ogundinmu Marvelous O., Oyebamiji David A., Oladunni Opeyemi, Okorie Anyaele O., Adejumobi Musibau O., Ayeleso Ademola O., Odaibo Alexander B.. Immunological Biomarkers and Epidemiological Evaluation of Lymphatic Filariasis Elimination Efforts in Osun State, Nigeria. International Journal of Tropical Medicines. 2026; 03(01):-.
How to cite this URL:
Nzekwe Samuel C, Babarinde Samuel O., Morakinyo Adetoun E., Boladale Abiodun L., Adeyemo Tolulope A., Kehinde Damilale O., Adeyemo Temitayo A., Ogundinmu Marvelous O., Oyebamiji David A., Oladunni Opeyemi, Okorie Anyaele O., Adejumobi Musibau O., Ayeleso Ademola O., Odaibo Alexander B.. Immunological Biomarkers and Epidemiological Evaluation of Lymphatic Filariasis Elimination Efforts in Osun State, Nigeria. International Journal of Tropical Medicines. 2026; 03(01):-. Available from: https://journals.stmjournals.com/ijtm/article=2026/view=236625


References

1. Joshi RS. Remodeling of lymphatic vessels during chronic filariasis. Lymphat Res Biol. 2021;19(2):142–149. doi:10.1089/lrb.2020.0065. 2. Kwarteng A, Mensah C, Osei-Poku P. Eosinophils as innate immune cells with anti-filarial vaccine and biomarker potential. Health Sci Rep. 2023;6(6):e1320. doi:10.1002/hsr2.1320. 3. Newman M, Juergens C. Recurrent lymphangitis in lymphatic filariasis: clinical challenges and management. Clin Infect Dis. 2021;72(5):912–918. doi:10.1093/cid/ciaa156. 4. World Health Organization. Lymphatic filariasis. Geneva: WHO; 2020 [cited 2025 Apr 9]. Available from: https://www.who.int/news-room/fact-sheets/detail/lymphatic-filariasis 5. Pfarr KM, Debrah AY, Specht S. Life cycle and host–pathogen interactions of Wuchereria bancrofti. Trends Parasitol. 2019;35(5):370–383. doi:10.1016/j.pt.2019.02.008. 6. Zeldenryk LM, Gray M, Redmond A. Understanding lymphatic filariasis disability and morbidity: a clinical review. Negl Trop Dis Rep. 2020;8(1):22–30. 7. Metenou S, Babu S, Nutman TB. Metabolic adaptations of filarial parasites to host environments. Parasite Immunol. 2021;43(4):e12842. doi:10.1111/pim.12842. 8. Babu S, Metenou S, Nutman TB. Host–parasite interactions in lymphatic filariasis: immune evasion and immunoregulation. Front Immunol. 2021;12:680783. doi:10.3389/fimmu.2021.680783. 9. Babu S, Nutman TB. Immunoregulation in lymphatic filariasis: perspectives from human studies. Parasitology. 2021;148(2):123–138. doi:10.1017/S0031182020001570. 10. Mukherjee S, Sinha B, Ghosh S. Immune response profiling in lymphatic filariasis patients with varying clinical phenotypes. PLoS One. 2019;14(4):e0214914. doi:10.1371/journal.pone.0214914. 11. Kumar NP, Anuradha R, George PJ, Nutman TB. Antibody subclass and cytokine responses in lymphatic filariasis. PLoS Negl Trop Dis. 2020;14(7):e0008395. doi:10.1371/journal.pntd.0008395. 12. Ebbo M, Crinier A, Vély F, Vivier E. IgG4 and immune dysfunction in filariasis. Trends Immunol. 2021;42(3):224–237. doi:10.1016/j.it.2021.01.003. 13. Bouchery T, Volkmann L, Amalvict R, Zeller M, Allen JE. Antibody-dependent cell- mediated cytotoxicity in helminth infections. PLoS Pathog. 2020;16(10):e1008744. doi:10.1371/journal.ppat.1008744. 14. Senbagavalli P, Anitha A, Arunagiri K. Complement activation in filarial infections. Indian J Immunol. 2021;18(3):221–229. 15. Rajamanickam A, Babu S. Unraveling the dynamics of human filarial infections: immunological responses, host manifestations, and pathogen biology. Pathogens. 2025;14(3):223. doi:10.3390/pathogens14030223. 16. Richards FO, Eigege A, Miri ES, Kal A, Umaru J, Pam D, et al. Epidemiological evaluations after six years or more of mass drug administration for lymphatic filariasis elimination in Nigeria. PLoS Negl Trop Dis. 2011;5(10):e1346. doi:10.1371/journal.pntd.0001346. 17. Biritwum NK, de Souza DK, Marfo B, Odoom S, Gyapong JO. Progress towards elimination of lymphatic filariasis in Ghana. Trans R Soc Trop Med Hyg. 2017;111(6):300–307. doi:10.1093/trstmh/trx048. 18. Dorkenoo MA, Bronzan R, Yehadji D, Maman I, Soldahlon Y. Surveillance for lymphatic filariasis after stopping mass drug administration in endemic districts of Togo, 2010–2015. Parasites Vectors. 2018;11(1):244. doi:10.1186/s13071-018-2806-7. 19. Anuradha R, George PJ, Hanna LE, Kumaran P, Nutman TB. The role of platelets in immune responses against filarial worms. Immunol Lett. 2020;228:75–82. doi:10.1016/j.imlet.2020.09.004. 20. Lee SH, Park HJ, Kim DS. Immunomodulatory therapy in lymphatic filariasis. Int J Mol Sci. 2023;24(7):3221. doi:10.3390/ijms24073221. 21. Jones MK, Alexander NDE, Beach RF. Regulatory T cells in filarial infections. Immunol Cell Biol. 2021;99(2):129–137. doi:10.1111/imcb.12405. 22. Babu S, Nutman TB. Immunopathogenesis of lymphatic filarial disease. Parasite Immunol. 2020;42(3):e12724. doi:10.1111/pim.12724.

Ahead of Print Subscription Review Article
Volume 03
01
Received 07/11/2025
Accepted 08/11/2025
Published 25/01/2026
Publication Time 79 Days
80

Login


My IP

PlumX Metrics